The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
Nuvectis Pharma (NVCT) announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a ...
In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public ...
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...